Ameriprise’s AbbVie ABBV Stock Holding History

Ameriprise’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.41B	Buy	11,068,310 +1,007,672	+10%	+$224M	0.56%	22
2025 Q4	$2.3B	Buy	10,060,638 +384,761	+4%	+$87.6M	0.52%	28
2025 Q3	$2.24B	Buy	9,675,877 +408,426	+4%	+$83.2M	0.51%	27
2025 Q2	$1.72B	Sell	9,267,451 -3,127,890	-25%	-$581M	0.42%	32
2025 Q1	$2.6B	Sell	12,395,341 -635,327	-5%	-$124M	0.7%	16
2024 Q4	$2.32B	Sell	13,030,668 -809,440	-6%	-$149M	0.59%	22
2024 Q3	$2.73B	Sell	13,840,108 -209,515	-1%	-$39.1M	0.7%	13
2024 Q2	$2.41B	Sell	14,049,623 -154,584	-1%	-$25.6M	0.65%	17
2024 Q1	$2.59B	Buy	14,204,207 +12,090	+0.1%	+$2.08M	0.71%	14
2023 Q4	$2.2B	Buy	14,192,117 +126,035	+0.9%	+$18.4M	0.66%	17
2023 Q3	$2.1B	Buy	14,066,082 +199,833	+1%	+$29.3M	0.69%	19
2023 Q2	$1.87B	Sell	13,866,249 -851,539	-6%	-$125M	0.59%	25
2023 Q1	$2.35B	Buy	14,717,788 +1,463,681	+11%	+$224M	0.77%	12
2022 Q4	$2.14B	Buy	13,254,107 +224,116	+2%	+$34.4M	0.73%	14
2022 Q3	$1.75B	Buy	13,029,991 +75,787	+0.6%	+$10.9M	0.65%	23
2022 Q2	$1.98B	Buy	12,954,204 +47,114	+0.4%	+$7.2M	0.69%	17
2022 Q1	$2.09B	Sell	12,907,090 -223,127	-2%	-$32.4M	0.62%	23
2021 Q4	$1.77B	Buy	13,130,217 +2,665,628	+25%	+$315M	0.49%	33
2021 Q3	$1.13B	Buy	10,464,589 +2,842,328	+37%	+$325M	0.36%	54
2021 Q2	$858M	Sell	7,622,261 -786,065	-9%	-$88.5M	0.27%	75
2021 Q1	$911M	Buy	8,408,326 +228,338	+3%	+$24.4M	0.3%	64
2020 Q4	$877M	Buy	8,179,988 +211,677	+3%	+$20.3M	0.31%	61
2020 Q3	$697M	Sell	7,968,311 -62,686	-0.8%	-$5.9M	0.28%	71
2020 Q2	$789M	Buy	8,030,997 +705,784	+10%	+$62.1M	0.34%	56
2020 Q1	$558M	Buy	7,325,213 +945,863	+15%	+$80.6M	0.29%	71
2019 Q4	$565M	Sell	6,379,350 -31,981	-0.5%	-$2.66M	0.23%	85
2019 Q3	$491M	Buy	6,411,331 +2,664,786	+71%	+$183M	0.22%	92
2019 Q2	$271M	Buy	3,746,545 +407,876	+12%	+$32.1M	0.12%	180
2019 Q1	$268M	Sell	3,338,669 -316,939	-9%	-$25.9M	0.12%	183
2018 Q4	$338M	Buy	3,655,608 +129,270	+4%	+$11.4M	0.17%	125
2018 Q3	$547M	Buy	3,526,338 +844,429	+31%	+$80.1M	0.19%	112
2018 Q2	$248M	Sell	2,681,909 -2,216,636	-45%	-$216M	0.11%	195
2018 Q1	$464M	Sell	4,898,545 -1,581,602	-24%	-$174M	0.21%	99
2017 Q4	$627M	Sell	6,480,147 -769,441	-11%	-$72.5M	0.29%	72
2017 Q3	$647M	Sell	7,249,588 -2,448,791	-25%	-$186M	0.31%	70
2017 Q2	$705M	Sell	9,698,379 -304,132	-3%	-$20.4M	0.35%	56
2017 Q1	$652M	Buy	10,002,511 +751,271	+8%	+$47.2M	0.34%	61
2016 Q4	$579M	Sell	9,251,240 -1,070,240	-10%	-$65.3M	0.32%	61
2016 Q3	$651M	Sell	10,321,480 -43,304	-0.4%	-$2.8M	0.36%	53
2016 Q2	$642M	Buy	10,364,784 +3,562,980	+52%	+$217M	0.38%	53
2016 Q1	$388M	Buy	6,801,804 +637,356	+10%	+$35.5M	0.23%	94
2015 Q4	$365M	Buy	6,164,448 +1,736,183	+39%	+$100M	0.21%	100
2015 Q3	$240M	Sell	4,428,265 -2,896,052	-40%	-$189M	0.15%	141
2015 Q2	$492M	Buy	7,324,317 +1,533,948	+26%	+$100M	0.28%	74
2015 Q1	$339M	Sell	5,790,369 -3,203,779	-36%	-$194M	0.19%	115
2014 Q4	$589M	Sell	8,994,148 -3,350,250	-27%	-$211M	0.34%	70
2014 Q3	$713M	Sell	12,344,398 -1,247,300	-9%	-$69.2M	0.43%	41
2014 Q2	$767M	Buy	13,591,698 +1,408,273	+12%	+$73.9M	0.45%	39
2014 Q1	$626M	Buy	12,183,425 +449,771	+4%	+$22.7M	0.38%	54
2013 Q4	$620M	Buy	11,733,654 +1,579,613	+16%	+$77.6M	0.38%	52
2013 Q3	$454M	Sell	10,154,041 -386,987	-4%	-$17.2M	0.3%	63
2013 Q2	$436M	Buy	+10,541,028	New	+$461M	0.3%	62

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Ameriprise's ABBV Position: Q1 2026 in Review

Ameriprise increased its AbbVie (ABBV) stake by 10% in Q1 2026, buying an estimated $224M and bringing the position to 11,068,310 shares worth $2.41B. The position accounts for 0.56% of the portfolio, ranked #22.

Ameriprise first reported a position in ABBV in Q2 2013 and has held it in 52 quarters since. The position peaked at $2.73B in Q3 2024. 4,077 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Ameriprise held 11,068,310 shares of AbbVie worth $2.41B as of Q1 2026.
Ameriprise bought 1,007,672 AbbVie shares in Q1 2026, an estimated $224M.
AbbVie made up 0.56% of Ameriprise's portfolio in Q1 2026, its #22 holding.
Ameriprise first reported a position in AbbVie in Q2 2013 and has held it in 52 quarters since.
Ameriprise's AbbVie position peaked at $2.73B in Q3 2024.
4,077 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Ameriprise's 13F filing for Q1 2026, filed 15 May 2026.